Biotech Values

[iwfal]

From the Phase II 900 patient trial can you please explain how many patients would have had a peak CK-MB greater than or equal to 100ng/ml to put it in proper perspective and show why the failure of the primary endpt of 50ng/ml is significant?

The answer is about 50 in the placebo arm assuming it is 300 patients per arm.

FWIW. (and it was somewhere near 15 +/- 3 that had "physician diagnosed MI" in the placebo arm)